Related Experiment Videos
Current concepts on monoclonal gammopathies.
1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Australian and New Zealand Journal of Medicine
|June 1, 1992
Summary
Monoclonal gammopathies, involving abnormal proteins, require lifelong monitoring. A significant percentage of patients initially diagnosed with benign monoclonal gammopathy later develop serious conditions like multiple myeloma.
Area of Science:
- Hematology
- Immunology
Background:
- Monoclonal gammopathies are characterized by the production of a monoclonal protein by B lymphocytes.
- Understanding the roles of T and B lymphocytes is crucial for diagnosing and managing these conditions.
Purpose of the Study:
- To review monoclonal gammopathies, including their causes and the roles of lymphocytes.
- To detail the recognition of monoclonal proteins in serum and urine.
- To examine the long-term outcomes and differentiation between benign and malignant forms.
Main Methods:
- Review of existing literature on monoclonal gammopathies.
- Analysis of a long-term follow-up study of 241 patients with apparently benign monoclonal gammopathy.
- Detailed examination of diagnostic criteria and patient monitoring.
Main Results:
- 22% of patients with apparently benign monoclonal gammopathy developed multiple myeloma, macroglobulinaemia, amyloidosis, or related disorders over long-term follow-up.
- The median time from monoclonal protein detection to serious disease development was 8-10 years.
- Malignancy can develop over 20 years later, necessitating indefinite patient follow-up.
Conclusions:
- Differentiating benign from malignant monoclonal gammopathies is critical and challenging.
- Long-term, indefinite monitoring is essential for patients with monoclonal gammopathies due to the risk of late-onset malignancy.
- Monoclonal gammopathies may be associated with other seemingly unrelated diseases.